慢性脫髓鞘多發性神經炎市場：按分銷管道、給藥途徑和地區分析與預測（2025 年至 2035 年）

慢性脫髓鞘多發性神經炎市場的主要成長要素之一是對創新有效治療方法的需求不斷增加。

隨著醫護人員和患者對慢性脫髓鞘多發性神經炎認知的不斷提高，該疾病的診斷率顯著上升，對更先進治療方法的需求也隨之增加。由於靜脈注射免疫球蛋白 (IVIG) 和血漿置換等傳統治療方法並非對所有患者都有效，因此針對生物製藥和口服免疫抑制劑等新治療方案有助於提供更個人化和有效的護理。

此外，慢性脫髓鞘多發性神經炎）認知度的提高、診斷技術的進步以及全球自體免疫疾病的增多，也促進了患者群體的擴大。隨著越來越多的患者在早期得到診斷，對能夠更快、更持久緩解症狀的治療方法的需求也日益成長，這推動了市場的成長。尤其是新型生物製藥（例如Vyvgart等FcRn抑制劑）的開發，它們直接作用於免疫介導機制，從而提高了治療效果並減少了副作用。

總體而言，注重提高治療的複雜性和患者的治療結果是推動慢性脫髓鞘多發性神經炎市場成長的關鍵因素。

然而，市場仍存在諸多挑戰，阻礙市場擴張。首要障礙是治療費用高。靜脈注射免疫球蛋白（IVIG）、血漿置換和生物製藥等治療方法價格昂貴，而慢性脫髓鞘多發性神經炎神經病變需要長期持續治療，頻繁治療給患者和醫療保健系統都帶來了沉重的經濟負擔。此外，FcRn抑制劑等新型生物製藥的高昂價格進一步加劇了這個問題，使得患者難以獲得治療，尤其是在醫療資源匱乏的地區。

另一個關鍵挑戰是，慢性脫髓鞘多發性神經炎是一種罕見疾病，其症狀與其他神經系統疾病如格林-巴利症候群（GBS）有重疊，經常導致誤診或延遲診斷，這常常導致在神經病變晚期才進行診斷，從而限制了治療的效果。

此外，儘管新治療方法的研發取得了進展，但某些亞型（例如難治性疾病）的治療選擇仍然有限。對於靜脈注射免疫球蛋白（IVIG）和血漿置換等第一線治療無效的患者，仍需要大量的有效第二線治療。

最後，類固醇和靜脈注射免疫球蛋白（IVIG）等傳統療法的副作用也會對一些患者造成困擾，使得長期治療難以持續。因此，尋找副作用較少的有效治療方法是該市場未來發展的關鍵挑戰之一。

本報告調查了全球慢性脫髓鞘多發性神經炎市場，並總結了主要趨勢、市場影響因素分析、法律制度、技術和專利分析、臨床試驗趨勢、市場規模趨勢和預測、各個細分市場、地區/主要國家、競爭格局的詳細分析以及主要企業的概況。

目錄

執行摘要

第1章全球慢性脫髓鞘多發性神經炎市場：產業展望

• 市場趨勢
• 法律規範
• 流行病學分析
• 臨床試驗分析
• 市場動態
  • 影響分析
  • 市場促進因素
  • 市場挑戰
  • 市場機會

2. 全球慢性脫髓鞘多發性神經炎市場（依通路）

• 醫院藥房
• 零售藥局
• 網路藥局

第3章全球慢性脫髓鞘多發性神經炎市場（依給藥途徑）

• 靜脈
• 口服
• 其他

4. 全球慢性脫髓鞘多發性神經炎市場（按地區）

• 北美洲
  • 主要發現
  • 市場動態
  • 市場規模及預測
• 歐洲
  • 主要發現
  • 市場動態
  • 市場規模及預測
• 亞太地區
  • 主要發現
  • 市場動態
  • 市場規模及預測
• 世界其他地區
  • 主要發現
  • 市場動態
  • 市場規模及預測

5. 全球慢性脫髓鞘多發性神經炎市場：競爭格局與公司概況

• 關鍵策略和發展
  • M&A
  • 協同活動
  • 業務擴展和資金籌措
  • 產品發布和核准
  • 其他活動
• 公司簡介
  • Sanofi
  • Grifols, SA
  • Kedrion Biopharma Inc.
  • Octapharma AG
  • AstraZeneca s (Alexion Pharmaceuticals, Inc.)
  • Argenx SE
  • Amgen (Horizon Therapeutics plc)
  • Biogen Inc.
  • GlaxoSmithKline (Human Genome Sciences, Inc.)
  • Pfizer Inc.
  • Takeda Pharmaceutical Company

第6章調查方法

Global Chronic Inflammatory Demyelinating Polyneuropathy Market, Analysis and Forecast: 2025-2035

Chronic inflammatory demyelinating polyneuropathy is a rare autoimmune disorder that primarily affects the peripheral nervous system. It is characterized by inflammation and demyelination (damage to the protective covering of nerves) of the nerve fibers, which leads to muscle weakness, sensory disturbances, and reduced reflexes. Chronic inflammatory demyelinating polyneuropathy is considered the chronic counterpart of Guillain-Barre syndrome (GBS), although chronic inflammatory demyelinating polyneuropathy tends to progress more slowly and is often recurrent.

Chronic inflammatory demyelinating polyneuropathy occurs when the body's immune system mistakenly attacks the myelin sheath, which insulates nerve fibers and allows for efficient nerve signal transmission. As a result, nerve conduction becomes impaired, leading to symptoms such as numbness, tingling, weakness, and pain in the limbs. Over time, if left untreated, Chronic inflammatory demyelinating polyneuropathy can cause permanent nerve damage and disability.

The disease can affect individuals of any age but is most commonly diagnosed in adults between the ages of 40 and 60. The cause of Chronic inflammatory demyelinating polyneuropathy is not fully understood, but it is thought to involve genetic predisposition and environmental factors that trigger an immune response. Chronic inflammatory demyelinating polyneuropathy is often treated with therapies that modify the immune system, such as intravenous immunoglobulin (IVIG), plasma exchange, and immunosuppressive drugs.

Early diagnosis and treatment are crucial for preventing long-term disability and improving the patient's quality of life. With proper management, many individuals with Chronic inflammatory demyelinating polyneuropathy can experience symptom relief and regain lost functionality.

One of the key drivers of the Chronic Inflammatory Demyelinating Polyneuropathy market is the growing demand for innovative and effective treatments. As awareness of Chronic inflammatory demyelinating polyneuropathy increases, both among healthcare providers and patients, there is a significant rise in the diagnosis rate of the disease. This, in turn, is driving the demand for more advanced therapies to manage the condition, especially as traditional treatments like IVIG (intravenous immunoglobulin) and plasma exchange may not be effective for all patients. The introduction of targeted biologic therapies and oral immunosuppressive treatments has opened up new treatment avenues, providing more personalized and effective care options for Chronic inflammatory demyelinating polyneuropathy patients.

Additionally, the increased awareness of Chronic inflammatory demyelinating polyneuropathy, improved diagnostic capabilities, and the growing prevalence of autoimmune diseases globally are contributing to the expanding patient pool. As more patients are diagnosed early, the need for innovative therapies that can offer faster, more sustained relief from symptoms is driving market growth. Furthermore, the development of new biologic therapies like FcRn inhibitors (e.g., Vyvgart) is addressing the immune-mediated mechanisms at the core of Chronic inflammatory demyelinating polyneuropathy, leading to better patient outcomes and fewer side effects.

Overall, the focus on advancing treatment options and improving patient outcomes is a key factor driving the growth of the Chronic inflammatory demyelinating polyneuropathy market.

Despite the growth of the Chronic Inflammatory Demyelinating Polyneuropathy market, several challenges continue to hinder its progress. One of the primary obstacles is the high cost of treatment, particularly for therapies such as intravenous immunoglobulin (IVIG), plasma exchange, and biologic therapies. These treatments can be expensive, especially considering that Chronic inflammatory demyelinating polyneuropathy often requires long-term management with frequent administration, leading to significant financial burden for both patients and healthcare systems. In addition, the high cost of novel biologic treatments, such as FcRn inhibitors, further compounds this challenge, limiting accessibility, particularly in regions with limited healthcare resources.

Another key challenge is the underdiagnosis and misdiagnosis of Chronic inflammatory demyelinating polyneuropathy. Given its rare nature and the overlap of symptoms with other neurological disorders like Guillain-Barre syndrome (GBS), Chronic inflammatory demyelinating polyneuropathy is often misdiagnosed or diagnosed at later stages when nerve damage has already occurred. This delay in diagnosis can lead to worsened patient outcomes and a lack of timely intervention, affecting the effectiveness of treatment.

Additionally, while there has been significant progress in the development of new therapies, the lack of treatment options for specific subtypes of Chronic inflammatory demyelinating polyneuropathy, such as refractory Chronic inflammatory demyelinating polyneuropathy, remains a major hurdle. Some patients do not respond adequately to first-line therapies like IVIG or plasma exchange, and finding effective second-line treatments for these patients remains an area of unmet need.

Finally, side effects from traditional treatments like steroids and IVIG can be problematic for some patients, limiting their ability to adhere to long-term treatment regimens. As a result, finding therapies that are both effective and have fewer side effects remains a critical challenge in the Chronic inflammatory demyelinating polyneuropathy market.

In conclusion, while the chronic inflammatory demyelinating polyneuropathy market is experiencing growth, costly treatments, diagnostic challenges, limited treatment options for refractory cases, and side effects continue to present barriers that need to be addressed to fully realize the potential of Chronic inflammatory demyelinating polyneuropathy market.

The global Chronic Inflammatory Demyelinating Polyneuropathy market is highly competitive, with several key players driving innovation and market growth. Leading companies such as Grifols, Kedrion Biopharma, Octapharma, Alexion Pharmaceuticals (now part of AstraZeneca), Argenx, Horizon Therapeutics (acquired by Amgen), and Biogen are at the forefront of providing treatments for chronic inflammatory demyelinating polyneuropathy. These companies are heavily involved in the development of intravenous immunoglobulin (IVIG) therapies, which are the mainstay of chronic inflammatory demyelinating polyneuropathy treatment. In addition, Argenx has introduced Vyvgart (efgartigimod), a FcRn inhibitor, which has shown promise in treating chronic inflammatory demyelinating polyneuropathy by modulating the immune system and reducing autoantibody activity.

As the market for chronic inflammatory demyelinating polyneuropathy treatments expands, these companies are also investing in new, innovative therapies that go beyond traditional immunoglobulin treatments. Biogen and Horizon Therapeutics, for example, are exploring biologic therapies and immune modulators, which can offer more targeted treatments for patients with chronic inflammatory demyelinating polyneuropathy. The competition is also driven by the increasing demand for personalized treatments and more effective solutions that can provide long-term relief, as current therapies often involve regular infusions and do not cure the disease.

These leading companies are contributing to the growing range of treatment options for chronic inflammatory demyelinating polyneuropathy, ultimately improving patient outcomes and quality of life. As the disease remains underdiagnosed in many cases, the focus on early diagnosis and innovative treatments is expected to drive further growth in the chronic inflammatory demyelinating polyneuropathy market.

Chronic Inflammatory Demyelinating Polyneuropathy Market Segmentation:

Segmentation 1: by Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Segmentation 2: by Route of Administration

• Intravenous
• Oral
• Others

Segmentation 3: by Region

• North America
• Europe
• Asia-Pacific
• Rest of the World

The global Chronic Inflammatory Demyelinating Polyneuropathy market is experiencing significant transformation driven by several emerging trends. There is a growing emphasis on personalized medicine, with advancements in biomarker identification and genomic testing allowing for more targeted and effective treatments for patients with chronic inflammatory demyelinating polyneuropathy. This approach is enabling healthcare providers to tailor therapies to individual patients, improving outcomes and reducing side effects.

Additionally, innovative therapies are reshaping the treatment landscape. For example, FcRn inhibitors like Vyvgart (efgartigimod) from Argenx are offering a new way to treat chronic inflammatory demyelinating polyneuropathy by modulating the immune system to reduce the autoantibodies that attack peripheral nerves. This has opened up new possibilities for patients who do not respond well to traditional intravenous immunoglobulin (IVIG) treatments.

There is also a rise in the use of biologic therapies and immune modulators, which are moving beyond conventional IVIG treatments and targeting the underlying immune processes more specifically. Companies like Biogen and Horizon Therapeutics are developing therapies that offer more targeted, long-term relief for chronic inflammatory demyelinating polyneuropathy patients.

Chronic inflammatory demyelinating polyneuropathy market is also benefiting from improved diagnostic techniques that allow for earlier and more accurate identification of chronic inflammatory demyelinating polyneuropathy. With better awareness and more advanced tools, physicians are able to detect chronic inflammatory demyelinating polyneuropathy earlier, leading to timely interventions that can reduce disease progression and improve patient quality of life.

Finally, increased patient advocacy and awareness campaigns are helping to raise the profile of chronic inflammatory demyelinating polyneuropathy, ensuring that more patients are diagnosed and treated appropriately. These efforts are helping drive demand for new therapies and solutions, accelerating the growth of the chronic inflammatory demyelinating polyneuropathy market.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Chronic Inflammatory Demyelinating Polyneuropathy Market: Industry Outlook

• 1.1 Introduction
• 1.2 Market Trends
• 1.3 Regulatory Framework
• 1.4 Epidemiology Analysis
• 1.5 Clinical Trial Analysis
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Challenges
  • 1.6.4 Market Opportunities

2. Global Chronic Inflammatory Demyelinating Polyneuropathy Market (by Distribution Channel), ($Billion), 2023-2035

• 2.1 Hospital Pharmacy
• 2.2 Retail Pharmacy
• 2.3 Online Pharmacy

3. Global Chronic Inflammatory Demyelinating Polyneuropathy Market (by Route of Administration), ($Billion), 2023-2035

• 3.1 Intravenous
• 3.2 Oral
• 3.3 Others

4. Global Chronic Inflammatory Demyelinating Polyneuropathy Market (Region), ($Billion), 2023-2035

• 4.1 North America
  • 4.1.1 Key Findings
  • 4.1.2 Market Dynamics
  • 4.1.3 Market Sizing and Forecast
    • 4.1.3.1 North America Chronic Inflammatory Demyelinating Polyneuropathy Market, by Country
      • 4.1.3.1.1 U.S.
• 4.2 Europe
  • 4.2.1 Key Findings
  • 4.2.2 Market Dynamics
  • 4.2.3 Market Sizing and Forecast
    • 4.2.3.1 Europe Chronic Inflammatory Demyelinating Polyneuropathy Market, by Country
      • 4.2.3.1.1 Germany
      • 4.2.3.1.2 U.K.
      • 4.2.3.1.3 France
      • 4.2.3.1.4 Italy
• 4.3 Asia Pacific
  • 4.3.1 Key Findings
  • 4.3.2 Market Dynamics
  • 4.3.3 Market Sizing and Forecast
    • 4.3.3.1 Asia Pacific Chronic Inflammatory Demyelinating Polyneuropathy Market, by Country
      • 4.3.3.1.1 China
      • 4.3.3.1.2 Japan
• 4.4 Rest of the World
  • 4.4.1 Key Findings
  • 4.4.2 Market Dynamics
  • 4.4.3 Market Sizing and Forecast

5. Global Chronic Inflammatory Demyelinating Polyneuropathy Market: Competitive Landscape and Company Profiles

• 5.1 Key Strategies and Development
  • 5.1.1 Mergers and Acquisitions
  • 5.1.2 Synergistic Activities
  • 5.1.3 Business Expansions and Funding
  • 5.1.4 Product Launches and Approvals
  • 5.1.5 Other Activities
• 5.2 Company Profiles
  • 5.2.1 Sanofi
    • 5.2.1.1 Overview
    • 5.2.1.2 Top Products / Product Portfolio
    • 5.2.1.3 Top Competitors
    • 5.2.1.4 Target Customers/End-Users
    • 5.2.1.5 Key Personnel
    • 5.2.1.6 Analyst View
  • 5.2.2 Grifols, S.A.
    • 5.2.2.1 Overview
    • 5.2.2.2 Top Products / Product Portfolio
    • 5.2.2.3 Top Competitors
    • 5.2.2.4 Target Customers/End-Users
    • 5.2.2.5 Key Personnel
    • 5.2.2.6 Analyst View
  • 5.2.3 Kedrion Biopharma Inc.
    • 5.2.3.1 Overview
    • 5.2.3.2 Top Products / Product Portfolio
    • 5.2.3.3 Top Competitors
    • 5.2.3.4 Target Customers/End-Users
    • 5.2.3.5 Key Personnel
    • 5.2.3.6 Analyst View
  • 5.2.4 Octapharma AG
    • 5.2.4.1 Overview
    • 5.2.4.2 Top Products / Product Portfolio
    • 5.2.4.3 Top Competitors
    • 5.2.4.4 Target Customers/End-Users
    • 5.2.4.5 Key Personnel
    • 5.2.4.6 Analyst View
  • 5.2.5 AstraZeneca s (Alexion Pharmaceuticals, Inc.)
    • 5.2.5.1 Overview
    • 5.2.5.2 Top Products / Product Portfolio
    • 5.2.5.3 Top Competitors
    • 5.2.5.4 Target Customers/End-Users
    • 5.2.5.5 Key Personnel
    • 5.2.5.6 Analyst View
  • 5.2.6 Argenx SE
    • 5.2.6.1 Overview
    • 5.2.6.2 Top Products / Product Portfolio
    • 5.2.6.3 Top Competitors
    • 5.2.6.4 Target Customers/End-Users
    • 5.2.6.5 Key Personnel
    • 5.2.6.6 Analyst View
  • 5.2.7 Amgen (Horizon Therapeutics plc)
    • 5.2.7.1 Overview
    • 5.2.7.2 Top Products / Product Portfolio
    • 5.2.7.3 Top Competitors
    • 5.2.7.4 Target Customers/End-Users
    • 5.2.7.5 Key Personnel
    • 5.2.7.6 Analyst View
  • 5.2.8 Biogen Inc.
    • 5.2.8.1 Overview
    • 5.2.8.2 Top Products / Product Portfolio
    • 5.2.8.3 Top Competitors
    • 5.2.8.4 Target Customers/End-Users
    • 5.2.8.5 Key Personnel
    • 5.2.8.6 Analyst View
  • 5.2.9 GlaxoSmithKline (Human Genome Sciences, Inc.)
    • 5.2.9.1 Overview
    • 5.2.9.2 Top Products / Product Portfolio
    • 5.2.9.3 Top Competitors
    • 5.2.9.4 Target Customers/End-Users
    • 5.2.9.5 Key Personnel
    • 5.2.9.6 Analyst View
  • 5.2.10 Pfizer Inc.
    • 5.2.10.1 Overview
    • 5.2.10.2 Top Products / Product Portfolio
    • 5.2.10.3 Top Competitors
    • 5.2.10.4 Target Customers/End-Users
    • 5.2.10.5 Key Personnel
    • 5.2.10.6 Analyst View
  • 5.2.11 Takeda Pharmaceutical Company
    • 5.2.11.1 Overview
    • 5.2.11.2 Top Products / Product Portfolio
    • 5.2.11.3 Top Competitors
    • 5.2.11.4 Target Customers/End-Users
    • 5.2.11.5 Key Personnel
    • 5.2.11.6 Analyst View

6. Research Methodology

List of Figures

Figure Global Chronic Inflammatory Demyelinating Polyneuropathy Market (by Region), $Billion, 2024 and 2035

Figure Global Chronic Inflammatory Demyelinating Polyneuropathy Market Key Trends, Analysis

List of Tables

• Table Global Chronic Inflammatory Demyelinating Polyneuropathy Market Dynamics, Impact Analysis
• Table Global Chronic Inflammatory Demyelinating Polyneuropathy Market (by Distribution Channel), $Billion, 2024-2035
• Table Global Chronic Inflammatory Demyelinating Polyneuropathy Market (by Route of Administration), $Billion, 2024-2035
• Table Global Chronic Inflammatory Demyelinating Polyneuropathy Market (by Region), $Billion, 2024-2035